Khiron

KHIRON LIFE SCIENCES ANNOUNCES CEASE TRADE ORDER

Retrieved on: 
Saturday, May 6, 2023

The OSC does not view the Company as having met all of the eligibility criteria for the MCTO set out in National Policy 12-203 – Management Cease Trade Orders, and as a result, has issued a failure-to-file cease trade order (the "CTO") pursuant to National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions for the failure to file the Annual Filings by the Filing Deadline.

Key Points: 
  • The OSC does not view the Company as having met all of the eligibility criteria for the MCTO set out in National Policy 12-203 – Management Cease Trade Orders, and as a result, has issued a failure-to-file cease trade order (the "CTO") pursuant to National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions for the failure to file the Annual Filings by the Filing Deadline.
  • The Company's CFO, Mr. Michael O'Connor, has begun transitioning into the role and is working with the Company's appointed auditors to complete the Annual Filings as soon as possible.
  • The Company will issue a further news release once the Annual Filings have been made.
  • There is no assurance that the Company will be able to remedy its filing default and have the CTO revoked in a timely manner or at all.

KHIRON LIFE SCIENCES ANNOUNCES PRICING OF MARKETED OFFERING OF UNITS

Retrieved on: 
Friday, March 24, 2023

/NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/

Key Points: 
  • /NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/
    TORONTO, March 24, 2023 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce the pricing of its previously announced marketed public offering (the "Offering").
  • Pursuant to the Offering, the Company will issue units of the Company (each, a "Unit") at a price of C$0.05 per Unit (the "Offering Price").
  • The Offering will be conducted on a best efforts agency basis by Canaccord Genuity Corp. (the "Agent"), as agent and sole bookrunner.
  • The Over-Allotment Option may be exercised by the Agent to acquire Units, Unit Shares and/or Unit Warrants.

KHIRON LIFE SCIENCES ANNOUNCES OVERNIGHT MARKETED OFFERING

Retrieved on: 
Monday, March 13, 2023

/NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/

Key Points: 
  • /NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/
    TORONTO, March 13, 2023 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has launched an overnight marketed public offering (the "Offering") of the Company's units (each, a "Unit").
  • The Offering will be conducted on a best efforts agency basis by Canaccord Genuity Corp. (the "Agent"), as agent and sole bookrunner.
  • The Offering will be priced and sized in the context of the market, with such terms including the offering price of the Units and the exercise price of the Warrants ("Warrant Exercise Price") to be determined at the time of entering into an agency agreement for the Offering.
  • There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or specific terms of the Offering.